A recent study in a mouse model of mammary carcinoma showed that HH pathway inhibition with vismodegib remodels the gut microbiota and increases the proliferation of resident CD8+ T cells across the immune network in the colon [70] (Figure 2). The gene discussed is CD8A; the disease is breast carcinoma.